{"name":"Mohammed Milhem, MBBS","slug":"mohammed-milhem-mbbs","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Ascorbate","genericName":"Ascorbate","slug":"ascorbate","indication":"Other","status":"marketed"}]}],"pipeline":[{"name":"Ascorbate","genericName":"Ascorbate","slug":"ascorbate","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiiAFBVV95cUxNSHQ3bVdfemZUOWUxdVlLeDlNb3F5OFF6bzlueERtb25uRVI2ZHIzb1hhVEI5QmR3d2haS3p3Z1RGdzdBRHhLR1BTYzNxWWQ4d2pmaExFR0lOX0stSXNOelpzeHB5X2tVbG9Vd3pUX205b1pSR25BWFJyWWViLUg1MTdsaDUySElp?oc=5","date":"2022-02-25","type":"pipeline","source":"The University of Iowa","summary":"Iowa researchers, patients giving cancer plenty of fight - The University of Iowa","headline":"Iowa researchers, patients giving cancer plenty of fight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi9wFBVV95cUxNVzRocHZtYkhnbE05MDNQYUMyb3pDQV9oZXAxOTB1Sk9KSG5IUm1ZU0VIeDlWeGxadWFMZWJiMEx0MXRxV3czWkNoT3FuWWpaQ0sxMEpMUlJCZlM3dWtNNkhkV1FsWVBPM1hhZEh0MWQyeEZrUWxQUjRSb2xjalFFX2VTTWZhQVhjUjBJMHprbmYxc05JUjJJZWpJbkN3MVJ3dUZhWGtfRmR3WXNrdEF4N20yNXg4OEo4OGdLOUtmTnRYdFFINUpHekpRcU93YXl4NVIwSnBHUjd6Yy01SnJfem83Smw1ZmN5VHZjOFoyRTliM19pdEFr?oc=5","date":"2018-04-18","type":"pipeline","source":"drugdiscoverytrends.com","summary":"TLR9 Agonist CMP-001-Pembrolizumab Combination Shows Early Efficacy in Patients With Metastatic Melanoma Resistant to Anti-PD-1 - drugdiscoverytrends.com","headline":"TLR9 Agonist CMP-001-Pembrolizumab Combination Shows Early Efficacy in Patients With Metastatic Melanoma Resistant to An","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"marketed":1},"enrichmentLevel":2,"visitCount":6,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}